文献速递结核与非结核分枝杆菌

南非有条件现金转移与结核病检测前后咨询对患者结局及全程医疗流失的影响:一项随机对照试验

Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2025-02-06

在南非约翰内斯堡9家诊所开展的实用、开放标签、个体随机对照试验,纳入4110例接受肺结核检查的成人,1:1随机分配至干预组(检测前后咨询+有条件现金转移)或对照组(标准治疗)。381例确诊为利福平敏感肺结核,加权分析显示干预组不良结局风险显著低于对照组(RR 0.52,95%CI 0.33-0.82)。

要点

  • 干预包为检测前后结核病咨询联合有条件现金转移(每次R150)。
  • 确诊利福平敏感结核者中,干预组不良结局加权患病率15.9% vs 对照组28.6%。
  • 干预组治疗前流失5例(3.9%)vs 对照组22例(15.8%)。

核心结论

  • 包含检测前后结核病咨询与有条件现金转移的干预包显著降低了结核病不良患者结局的风险,使90-90-90目标之一(即达到90%结核病治疗成功)触手可及。
  • 治疗前流失的减少预期可随时间推移减少传播并降低疾病发病率。

研究设计与样本

  • 在南非约翰内斯堡9家诊所开展的实用、开放标签、个体随机对照试验。
  • 纳入年龄≥18岁接受结核病检查的参与者,按1:1随机分配至干预组或对照组(标准治疗),采用排列区组随机化并按诊所分层,使用不透明信封隐藏分组。
  • 干预组接受检测前后结核病咨询,确诊利福平敏感结核者还在治疗启动时及每次月度治疗访视时获得数字支付(R150,约10美元),支付以按时就诊为条件:初始痰标本采集后14天内,以及预定月度预约前后7天内。
  • 主要终点为成功患者结局(治愈或完成治疗)或不良患者结局(治疗前流失、治疗中流失、治疗期间出现利福平耐药结核、治疗失败[即开始治疗后5个月或更晚涂片或培养阳性]或死亡)。
  • 主要结局在改良意向治疗人群中分析,定义为所有随机分配且开始结核治疗前确认利福平敏感结核的参与者。

主要发现

  • 381例(9.3%)参与者有微生物学确认的利福平敏感肺结核(干预组2059例中195例[9.5%] vs 对照组2051例中186例[9.1%];中位年龄37岁[IQR 30至45],男性257例[67.5%],女性124例[32.5%])。
  • 研究结束时,干预组195例中128例(65.6%)和对照组186例中139例(74.7%)有主要结局数据。
  • 干预组128例中105例(82.0%)和对照组139例中93例(66.9%)为成功患者结局;干预组128例中23例(18.0%)和对照组139例中46例(33.1%)为不良患者结局。
  • 加权回归分析显示干预组不良患者结局风险较对照组大幅降低(加权患病率15.9% vs 28.6%;加权人群中RR 0.52,95%CI 0.33至0.82;加权人群中风险差-14.1个百分点,95%CI -23.3至-4.8)。
  • 干预组治疗前流失低于对照组(未加权人群:128例中5例[3.9%] vs 139例中22例[15.8%];加权人群中风险差-9.6个百分点,95%CI -14.9至-4.2)。

临床怎么用

  • 作者认为,包含检测前后结核病咨询与有条件现金转移的干预包可显著降低结核病不良患者结局风险,并使90%结核病治疗成功目标触手可及。
  • 作者指出,治疗前流失的减少预期可随时间推移减少传播并降低疾病发病率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Economic and behavioural factors lead to poor outcomes in patients with tuberculosis. We investigated the effects of a package of interventions consisting of pre-test and post-test tuberculosis counselling with conditional cash transfers on patient outcomes in adults undergoing investigation for pulmonary tuberculosis. METHODS: This pragmatic, open-label, individual randomised controlled trial was done in nine clinics in Johannesburg, South Africa. Participants (aged ≥18 years) undergoing investigation for tuberculosis were randomly assigned (1:1) to the intervention group or control group (standard of care) via permuted block randomisation, stratified by clinic; group assignment was concealed using opaque envelopes. The intervention group received pre-test and post-test tuberculosis counselling, and for participants diagnosed with rifampicin-susceptible tuberculosis, a digital payment (R150; approximately US$10) at treatment initiation and each monthly treatment visit. Payments were contingent on timely attendance: 14 days from initial sputum sample collection and within 7 days on either side of their scheduled monthly appointment. The primary endpoint was successful patient outcome (patients who were cured or completed treatment) or unsuccessful patient outcome (pretreatment loss-to-follow-up, on-treatment loss-to-follow-up, development of rifampicin-resistant tuberculosis while on treatment, treatment failure [ie, smear or culture positive at 5 months or later after commencing treatment], or death). The primary outcome was analysed in the modified intention-to-treat population, defined as all randomly assigned participants with rifampicin-susceptible tuberculosis confirmed before the commencement of tuberculosis treatment. Weighted outcome prevalence, relative risks (RRs), and risk differences were calculated using a multivariable Poisson model with robust standard errors. This trial is registered with the Pan African Clinical Trials Registry (PACTR202410708311054) and is completed. FINDINGS: Between Oct 25, 2018, and Dec 9, 2019, 4110 participants were enrolled and randomly assigned, 2059 to the intervention group and 2051 to the control group. 381 (9·3%) participants had microbiologically confirmed rifampicin-susceptible pulmonary tuberculosis (195 [9·5%] of 2059 in the intervention group vs 186 [9·1%] of 2051 in the control group; median age 37 years [IQR 30 to 45], 257 [67·5%] male, 124 [32·5%] female). At study closure, primary outcome data were available for 128 (65·6%) of 195 participants in the intervention group and 139 (74·7%) of 186 participants in the control group. 105 (82·0%) of 128 participants in the intervention group and 93 (66·9%) of 139 participants in the control group had a successful patient outcome; 23 (18·0%) of 128 participants in the intervention group and 46 (33·1%) of 139 participants in the control group had an unsuccessful patient outcome. The weighted regression analysis showed a substantial reduction in the risk of unsuccessful patient outcomes in the intervention group compared with the control group (weighted prevalence 15·9% vs 28·6%; RR in weighted population 0·52, 95% CI 0·33 to 0·82; risk difference in weighted population -14·1 percentage points, 95% CI -23·3 to -4·8). Pretreatment loss to follow-up was lower in the intervention group than in the control group (unweighted population: five [3·9%] of 128 participants vs 22 [15·8%] of 139 participants; risk difference in weighted population -9·6 percentage points, 95% CI -14·9 to -4·2). INTERPRETATION: The package of interventions consisting of pre-test and post-test tuberculosis counselling with conditional cash transfers significantly reduced the risk of unsuccessful tuberculosis patient outcomes, bringing one of the 90-90-90 targets within reach (ie, achieving 90% tuberculosis treatment success). Furthermore, reduction in pretreatment loss to follow-up is expected to reduce transmission and lower incidence of the disease over time. FUNDING: South African Medical Research Council, UK Medical Research Council, and Newton Fund.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ismail N, Moultrie H, Mwansa-Kambafwile J, et al. Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial. Lancet Infect Dis. 2025. PMID: 39923785. doi:10.1016/S1473-3099(24)00816-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。